Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea (WinMal)
WinMal Trial: Spatial Emanator Deployment Strategies for Malaria Control in Papua New Guinea
Malaria cases are increasing in Papua New Guinea, partly because insecticide-treated nets do not fully protect people, especially from mosquitoes that bite outdoors. Spatial emanators are new devices that release insecticide into the air to repel or kill mosquitoes. This study will test whether these devices reduce malaria infections in rural villages in Madang Province by comparing households using indoor or outdoor devices with those without them. The results will help guide national malaria control strategies.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The WinMal trial is a large-scale cluster randomised control trial investigating whether spatial emanators reduce transmission of malaria infections. The study is being conducted with 150 rural villages in Bogia, Sumkar, Madang and Rai Coast districts of Madang Province, Papua New Guinea.
The trial will address the question: 'Do Guardian spatial emanators reduce malaria transmission when deployed in protected outdoor spaces or inside houses in PNG?'
The trial will evaluate the effectiveness, acceptability and feasibility of Guardian SE deployed indoors and outdoors for malaria prevention in PNG.
The WinMal trial will provide evidence to guide PNG National Department of Health decisions on how spatial emanators could be deployed alongside ITNs to address gaps in protection from outdoor biting.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Paul Daly, MPH MID
- 전화번호: +61 3 9282 2111
- 이메일: paul.daly@burnet.edu.au
연구 장소
-
-
Madang Province
-
Madang, Madang Province, 파푸아 뉴기니
- Sumkar, Bogia, Rai Coast and Madang Districts of Madang Province, Papua New Guinea
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Children aged 9-14 years at enrolment
- Sleeps in a household within allocated cluster >90% of the nights during any given month
Exclusion Criteria:
- Dissent (by child) to participate in the study
- No parental consent provided through the signing of informed consent form
- Unwillingness to take G6PD-guided radical cure treatment at enrolment with no previous ADRs to AL or PQ
- Plans for extended travel (>2 weeks) outside of household/cluster during the study
- G6PD activity ≤6.0 U/g Hb at screening
- Measured baseline of ≤8 mg/dL or who have signs of clinical decompensation
- Participating or planning to participate in another clinical trial investigating a drug, vaccine, medical device, or procedure during the study period
- Currently taking malaria prophylaxis
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Outdoor intervention arm
Guardian spatial emanators deployed in protected outdoor spaces, households will continue to use ITNs as per routine National Malaria Control Program |
Guardian spatial emanators deployed in protected outdoor spaces |
|
실험적: Indoor intervention arm
Guardian spatial emanators deployed inside houses, households will continue to use ITNs as per routine National Malaria Control Program |
Guardian spatial emanators deployed inside houses |
|
간섭 없음: Control arm
No spatial emanators deployed, households will continue to use ITNs as per routine National Malaria Control Program |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Effectiveness of Guardian Spatial Emanator
기간: 12 months
|
Time to first Plasmodium spp. infection detected by PCR at monthly follow-up visits or symptomatic ad-hoc visit between follow-ups over the 12-month intervention period in cohort participants from the core of the clusters. |
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Effectiveness of Guardian Spatial Emanator
기간: 12 months
|
Time to first PCR-confirmed P. falciparum infection over the 12 months of follow-up. Time to first PCR-confirmed P. vivax infection over the 12 months of follow-up. |
12 months
|
|
Effectiveness of Guardian Spatial Emanator
기간: 6 months
|
Time to first PCR-confirmed Plasmodium spp infection over the first 6 months of follow-up. Time to first PCR-confirmed P. falciparum infection over the first 6 months of follow-up. Time to first PCR-confirmed P. vivax infection over the first 6 months of follow-up. |
6 months
|
|
Effectiveness of Guardian Spatial Emanator
기간: 12 months
|
Incidence of PCR-confirmed Plasmodium spp infections (first-time & recurrent together) in first 6m & full 12m. Incidence of PCR-confirmed Pf infections (first-time & recurrent together) in first 6m & full 12m. Incidence of PCR-confirmed Pv infections (first-time & recurrent together) in first 6m & full 12m Incidence of clinical episodes of malaria (first-time & recurrent together) in first 6m & full 12m Incidence of Pf clinical episodes of malaria (first-time & recurrent together) in first 6m & full 12m Incidence of Pv clinical episodes of malaria (first-time & recurrent together) in first 6m & full 12m Incidence of new Pf blood stage infections (molecular force of blood-stage infection - Pf molFOB) in first 6m & full 12m Incidence of new Pv blood stage infections (molecular force of blood-stage infection - Pv molFOB) in first 6m & full 12m Incidence of new blood stage infections (molecular force of blood-stage infection for Pf and Pv molFOB combined) in first 6m & full 12m |
12 months
|
|
Difference between indoor and outdoor arms
기간: 12 months
|
Time to first Plasmodium spp. infection detected by PCR at monthly follow-up or symptomatic ad-hoc visit between follow-ups visits over the 12-month intervention period in cohort participants from the core of the clusters. |
12 months
|
|
Sensitivity of the estimates for epidemiological outcomes
기간: 12 months
|
Spillover-adjusted estimates of intervention effectiveness for epidemiological endpoints, incorporating data from cluster buffer zone participants. |
12 months
|
|
Anopheles species composition
기간: 12 months
|
Anopheles species composition in a subset of clusters, in the pre-deployment baseline period and at the end of the intervention. |
12 months
|
|
Presence of insecticide resistance mutations
기간: 12 months
|
Prevalence of insecticide resistance markers in a subset of clusters in the pre-deployment baseline period and at the end of the intervention. |
12 months
|
|
Acceptability of spatial emanators
기간: 12 months
|
Qualitative outcomes from Photovoice methodology, and associated focus group discussions with community members, followed by thematic analysis of drivers of behaviour change, barriers and enablers of spatial emanator acceptance and consistent use. |
12 months
|
|
Feasibility of spatial emanators
기간: 12 months
|
Qualitative outcomes from key informant interviews with key study staff and health system stakeholders at district, provincial, and national level followed by descriptive summary of barriers and enablers to distribution, implementation & scale-up. |
12 months
|
|
Cost effectiveness of Guardian spatial emanators
기간: 12 months
|
The costs of deploying spatial emanators (either indoor or outdoor) and the incremental cost-effectiveness ratios when compared with current practice. |
12 months
|
|
Self-reported adverse events
기간: 12 months
|
Incidence of self-reported adverse events (AEs) and/or serious adverse events (SAEs) assessed as possibly or likely related to Guardian spatial emanators among cohort participants (through monthly follow-up) and wider community through passive surveillance. |
12 months
|
|
Coverage, attrition and re-location of spatial emanators
기간: 12 months
|
Proportion of households with emanators in place at scheduled monitoring visits, the attrition rate per cluster per scheduled monitoring visit period, timing of redistribution events recorded per cluster. |
12 months
|
|
Transfluthrin quantity, installation environment and bioefficacy
기간: 12 months
|
Mass percent transfluthrin retained in the spatial emanators related to installation environment and bioefficacy measure/s (e.g., knock down and mortality of colony mosquitoes exposed to spatial emanators). |
12 months
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
수사관
수사관
- 수석 연구원: Leanne Robinson, MPH PhD, Burnet Institute
- 수석 연구원: Moses Laman, MBBS PHD, Papua New Guinea Institute of Medical Research
- 수석 연구원: Stephan Karl, PhD, James Cook University, Queensland, Australia
- 수석 연구원: Jacob Kisomb, MBBS, National Department of Health, Papua New Guinea
- 수석 연구원: Maria Ome-Kaius, MBBS PhD, Papua New Guinea Institute of Medical Research
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- NATNAT WinMal cRCT
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .